Chief AI Officer, SynThx Rx L.L.C.

Bruce Changlong Xu, B.S., M.S. (Stanford) is the Chief Data Officer of SynThx Rx, where he spearheads innovations in RNA therapeutic discovery using advanced transformer-based architectures. With a background in computer science and translational medicine from Stanford University, Bruce brings a wealth of experience from diverse fields, including venture capital, deep technology, and digital health. Known for his impactful keynote speeches across industries, he has contributed to AI-based digital health investments at Google, conducted AI research in Sebastien Thrun’s lab at the Stanford Artificial Intelligence Laboratory, and developed neurosurgical applications in the Surgeon-Machine Interface Lab at Stanford Healthcare.

Bruce's career includes pivotal roles in designing Apple’s M2 Processor, NVIDIA’s DGX GPU architecture, and driving AI/infra across various billion-dollar high-technology companies in silicon valley; He has been involved in groundbreaking studies in cardio-oncology (Stanford CVI), translational medicine (UCSF), and digital health (Mayo Clinic/Kaiser Permanente). His work at SynThx Rx reflects a commitment to transforming healthcare through AI-driven precision medicine and RNA therapeutics.

Group Chief Executive Officer and Chief Financial Officer, SynThx Rx L.L.C.

Wu Lan, B.S, B.A, M.S. (Berkeley, Columbia CBS) is the Chief Financial Officer of SynThx Rx, bringing a wealth of experience across Pharmaceuticals, Venture Capital, Management, and Corporate Development. She was an early investor in pre-IPO biotechnology companies across North America, and worked on optimizing novel therapeutic pipelines at Genentech, Merck, and Bayer with cutting-edge technologies.

Lan has deep experience combining world-class management philosophy with the deep unmet needs of the patient populace, driving forward breakthrough therapies that transform the paradigm of compassionate care. Wu Lan has been involved in state-of-the-art spectroscopy research, mentored by a Wolf-prize in Chemistry Laureate, and co-founded multiple digital health ventures to advance patient care. Through SynThx Rx, Lan and Bruce are anticipating and contributing to the next generation of "techbio" innovations.

SynThx Rx LLC is a pioneering biotech subsidiary of OBPharm, dedicated to advancing AI-optimized mRNA therapeutics for cardio-protection and precision oncology. SynThx Rx focuses on developing innovative treatments for severe cardiac complications, including ischemia-reperfusion injury (IRI) and immune checkpoint inhibitor (ICI)-induced myocarditis—conditions that currently lack effective targeted therapies. Based in San Francisco Bay Area, SynThx Rx functions at the cutting edge of artificial intelligence, technology, academia, deep scientific breakthroughs and venture capital.

By leveraging cutting-edge artificial intelligence, SynThx Rx designs and optimizes mRNA constructs to deliver cardio-protective proteins that address key inflammatory and apoptotic pathways involved in both IRI and ICI-induced myocarditis. Through the integration of genomic, proteomic, and transcriptomic data, SynThx Rx aims to create highly stable, low-immunogenicity mRNA therapies tailored for specific cellular targets.

SynThx Rx’s mission is to transform cardio-protection and cardio-oncology by providing next-generation precision therapies that improve patient outcomes and redefine the possibilities of mRNA therapeutics in complex disease areas.